Latest News

View allAccessAL amyloidosisCAR-TConferencesMPEMyelomaNewsPatient evidenceSin categoríaVideos

MPE gives feedback on the proposed implementing act supporting the EU Health Technology Assessment regulation

The European Commission recently held an online public consultation on the first draft implementing act supporting the EU health technology assessment (HTA) regulation. The EU HTA regulation will be implemented from 2025 and aims to increase the collaboration on health technology assessment across EU member states. Implementing acts set out the legislative detail of different…

Read more

Sign up for the MPE webinar “AL amyloidosis treatment updates and patient experiences on new therapies”

Myeloma Patients Europe (MPE) will hold the webinar “AL amyloidosis treatment updates and patient experiences on new therapies” on Tuesday 16 April from 17:00 – 18:00 CEST. The webinar will be given by Dr. Moshe Gatt, Physician Researcher Haematologist at the Hebrew University of Jerusalem, Israel, along with two AL Amyloidosis patients from Israel, Naphtali Mastboim and Melvin Granatstein, who…

Read more

European Commission grants final approval for CAR-T treatment idecabtagene vicleucel (Abecma) in earlier lines of therapy for relapsed and refractory myeloma

The European Commission has granted the final approval for the extension of the marketing authorisation for idecabtagene vicleucel (ide-cel), a CAR-T treatment marketed by Bristol-Myers Squibb (BMS) as Abecma®. Ide-cel has previously been approved for the treatment of patients with relapsed and refractory myeloma, who have received at least three previous lines of therapy. The…

Read more

EMA CHMP gives positive recommendation on CAR T-cell therapy ciltacabtagene autoleucel in earlier lines of therapy for relapsed and refractory myeloma

The Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA – the EU medicines regulator) has today given a positive recommendation for the extension of the marketing authorisation for the CAR-T treatment ciltacabtagene autoleucel (Carvytki®), also known as cilta-cel, for use in patients who have received at least 1 prior…

Read more
January

February 2026

March
MO
TU
WE
TH
FR
SA
SU
26
27
28
29
30
31
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
1
Events for 1st February
No Events
Events for 2nd February
No Events
Events for 3rd February
No Events
Events for 4th February
No Events
Events for 5th February
No Events
Events for 6th February
No Events
Events for 7th February
No Events
Events for 8th February
No Events
Events for 9th February
No Events
Events for 10th February
No Events
Events for 11th February
No Events
Events for 12th February
No Events
Events for 13th February
No Events
Events for 14th February
No Events
Events for 15th February
No Events
Events for 16th February
No Events
Events for 17th February
No Events
Events for 18th February
No Events
Events for 19th February
No Events
Events for 20th February
No Events
Events for 21st February
No Events
Events for 22nd February
No Events
Events for 23rd February
No Events
Events for 24th February
No Events
Events for 25th February
No Events
Events for 26th February
No Events
Events for 27th February
No Events
Events for 28th February
No Events